Institute For Prostate Cancer Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 13-12-2024
- Paid Up Capital ₹ 0.10 M
as on 13-12-2024
- Company Age 13 Year, 28 Days
- Last Filing with ROC 31 Mar 2024
- Revenue -100.00%
(FY 2023)
- Profit 56.78%
(FY 2023)
- Ebitda -4.13%
(FY 2023)
- Net Worth -1.57%
(FY 2023)
- Total Assets -2.39%
(FY 2023)
About Institute For Prostate Cancer
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Aarti Upadhye and Dattatraya Joglekar serve as directors at the Company.
- CIN/LLPIN
U85100PN2011NPL141427
- Company No.
141427
- Company Classification
Private Not For Profit Company
- Incorporation Date
22 Nov 2011
- Date of AGM
02 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Institute For Prostate Cancer?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dattatraya Joglekar  | Additional Director | 01-Jan-2021 | Current |
| Aarti Upadhye | Additional Director | 01-Jan-2021 | Current |
Financial Performance and Corporate Structure Insights of Institute For Prostate Cancer.
Institute For Prostate Cancer, for the financial year ended 2023, experienced significant reduction in revenue, with a 100% decrease. The company also saw a substantial improvement in profitability, with a 56.78% increase in profit. The company's net worth dipped by a decrease of 1.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Institute For Prostate Cancer?
In 2023, Institute For Prostate Cancer had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Kalyani Infotech Solutions Private LimitedActive 27 years 10 monthsDattatraya Joglekar is a mutual person
Kalyani Agro Corporation LtdActive 33 years 6 monthsAarti Upadhye and Dattatraya Joglekar are mutual person
- Khed Wind Energy And Infra Projects Private LimitedActive 17 years 3 months
Aarti Upadhye is a mutual person
- Vishwasarh Finance Private LimitedActive 34 years 8 months
Aarti Upadhye and Dattatraya Joglekar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Institute For Prostate Cancer?
Unlock and access historical data on people associated with Institute For Prostate Cancer, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Institute For Prostate Cancer, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Institute For Prostate Cancer's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
